Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

BACKGROUND: Fatty acid-binding protein 4 (FABP4) acts as a novel adipokine, and elevated FABP4 concentration is associated with obesity, insulin resistance and atherosclerosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of antidiabetic drugs, have distinct structures among the drugs, possibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuhashi, Masato, Sakuma, Ichiro, Morimoto, Takeshi, Higashiura, Yukimura, Sakai, Akiko, Matsumoto, Megumi, Sakuma, Mio, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Node, Koichi, Ueda, Shinichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296623/
https://www.ncbi.nlm.nih.gov/pubmed/32539832
http://dx.doi.org/10.1186/s12933-020-01061-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296623/
https://www.ncbi.nlm.nih.gov/pubmed/32539832
http://dx.doi.org/10.1186/s12933-020-01061-0

Ejemplares similares